Contact us

Leading CDMO Companies in India

Your Trusted Partners in India for Contract Manufacturing

Applied Filters:APAC×Clear All
Showing 25 facilities
SENN India | Non-GMP Plant | Hyderabad, India
India

SENN India | Non-GMP Plant | Hyderabad, India

Senn Chemicals

Large scale non GMP manufacturing site for peptide intermediates, organic synthesis, LPPS operations and scale up production.

Discover our facility

BATCH SIZE: Small, Medium, Large

CATEGORY / PRODUCT: COSMETICS, SERVICES, PARTICLE ENGINEERING, CHEMICAL-SYNTHETIC

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

REGION: APAC

SENN India | R&D Lab | Hyderabad, India
India

SENN India | R&D Lab | Hyderabad, India

Senn Chemicals

R&D centre for peptide and organic chemistry with SPPS, purification, lyophilisation, analytics and particle engineering support.

Discover our facility

BATCH SIZE: Small

SERVICES: Analytical / QC services, Logistics, Development services, Packaging, Quality Assurance services

REGION: APAC

CATEGORY / PRODUCT: PARTICLE ENGINEERING, CHEMICAL-SYNTHETIC

Viswa Laboratories Pvt Ltd
India

Viswa Laboratories Pvt Ltd

Viswa Laboratories Private Limited

CRAMS/CDMO, APIs, Intermediates and specialty chemicals.

Discover our facility

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (M) Musculoskeletal system, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (D) Dermatologicals

CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse

MARKETS: ANVISA (Brazil), CDSCO (India), Russian Health Authorities, EMA (EU), NMPA (China)

USE: Human, Veterinary

COMPLIANCE: World Health Organization (GMP / HACCP)

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

SERVICES: Manufacturing services, Development services

BSL (Biological Safety Level): 1, 2

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

Hikal Ltd | Bangalore, India
India

Hikal Ltd | Bangalore, India

Hikal Ltd.

cGMP Process Development, Scale-up and Manufacturing of Small Molecule APIs, NMEs and Intermediates from grams to tones.

Discover our facility

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (C) Cardiovascular system, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (V06) Nutrients

COMPLIANCE: EMA (EU GMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), TGA (Australia GMP), FDA (cGMP), ECOVADIS, ISO, Halal Research Council, COFEPRIS

CATEGORY / PRODUCT: COSMETICS, SERVICES, NUTRACEUTICALS, CHEMICAL-SYNTHETIC

USE: Human, Veterinary

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

SERVICES: Manufacturing services, Development services

Register
Limited view

PARTICLE ENGINEERING manufacturing site

MAI network supplier

An API and Interemediate manufacturer having global certifications.

Location available after registration

Register for freeContact MAI to connect
Register
Limited view

SERVICES manufacturing site

MAI network supplier

GMP-compliant biologics manufacturing facility specializing in recombinant enzymes and proteins.

Location available after registration

Register for freeContact MAI to connect
Register
Limited view

COSMETICS manufacturing site

MAI network supplier

Small molecule drug substance development and manufacturing site.

Location available after registration

Register for freeContact MAI to connect
Suggested Results

These facilities match your main criteria but not every optional filter — including other countries in the same region.

Pharmaron API Commercial Synthesis Shaoxing (China)
China

Pharmaron API Commercial Synthesis Shaoxing (China)

Pharmaron

Commercial API Small Molecules /Peptides Synthesis.

Discover our facility

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

USE: Human, Veterinary

SERVICES: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Quality Assurance services

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

MARKETS: FDA (USA), NMPA (China)

COMPLIANCE: FDA (cGMP), NMPA (China GMP), ISO

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

CARBOGEN AMCIS | Shanghai, China
China

CARBOGEN AMCIS | Shanghai, China

CARBOGEN AMCIS

Large scale manufacturing.

Discover our facility

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (B) Blood and blood forming organs, (V06) Nutrients

CATEGORY / PRODUCT: SERVICES, OLIGONUCLEOTIDES, CHEMICAL-SYNTHETIC

USE: Human

COMPLIANCE: ANVISA (Brazil B-GMP), NMPA (China GMP)

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

Apeloa Pharmaceutical Co., Ltd.
China

Apeloa Pharmaceutical Co., Ltd.

Apeloa Pharmaceutical Co., Ltd

Apeloa CDMO provides world-class discovery, development, and manufacturing services for APIs, Intermediates, and RSMs.

Discover our facility

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium, Large

COMPLIANCE: EMA (EU GMP), PMDA/MHLW (Japan GMP), World Health Organization (GMP / HACCP), FDA (cGMP), NMPA (China GMP), ECOVADIS, ISO

USE: Human, Veterinary

SERVICES: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Packaging

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

Adragos Pharma | Kawagoe
Japan

Adragos Pharma | Kawagoe

Adragos Pharma

Our facility provides best-in-class manufacturing of tablets and ampoules.

Discover our facility

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, SERVICES

MARKETS: EDE (UAE), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)

COMPLIANCE: EMA (EU GMP), PMDA/MHLW (Japan GMP), FDA (cGMP)

BATCH SIZE: Large

CONTROLLED SUBSTANCES: Lowest potential for abuse, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse

USE: Human

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Packaging, Quality Assurance services

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

Sichuan Huiyu Pharmaceuticals Co., Ltd. - API Manufacturing Site
China

Sichuan Huiyu Pharmaceuticals Co., Ltd. - API Manufacturing Site

Seacross Pharmaceutical Co Ltd

As one of three core sites, alongside the R&D center and formulation plant, our API manufacturing facility plays a vital role in the integrated supply chain.

Discover our facility

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

COMPLIANCE: ISP (Chile BPM), Roszdravnadzor (Russia GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), PMDA/MHLW (Japan GMP), IFS, DIGEMID, UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), French Service-Public (CIR), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (China GMP), SFDA (Saudi Food & Drug Authority), BRCGS, ECOVADIS, ISO, Halal Research Council, INVIMA, Health Canada (Canada GMP), SQF (Safe Quality Food), TITCK (Turkish Health Authorities), MSPAS, MFDS/KFDA (Republic of Korea GMP), COFEPRIS

CONTROLLED SUBSTANCES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse

BSL (Biological Safety Level): 3, 4, 1, 2

USE: Human

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+18 more facilities

Create free account

India is a rapidly growing hub for pharmaceutical development and manufacturing, attracting global attention for its robust infrastructure and cost-efficient capabilities. CDMO companies in India are well-integrated into global supply chains, offering expertise in clinical trial supply, commercial manufacturing, and regulatory support aligned with FDA, EMA, and global standards.

From agile biotech innovators to multinational pharma companies, organizations partner with CDMOs in India for their technical expertise, regulatory compliance, and ability to scale rapidly across global markets.

Why Choose CDMOs in India?

India offers a unique value proposition: a skilled workforce, advanced pharmaceutical infrastructure, and strong regulatory track record with global health authorities. CDMOs in India are supported by government initiatives like PLI schemes and benefit from a cost-effective manufacturing environment and extensive global export network.

With proven experience in complex molecules, including high-potency APIs, biologics, and niche formulations, CDMOs in India are trusted partners for global drug development and commercialization programs.

Key Services Offered by CDMO Companies in India

  • Clinical Supply Manufacturing: Phase I–III production with accelerated timelines and global distribution capabilities.
  • Regulatory & Submission Support: Expertise in US FDA, EMA, DCGI, and ROW submissions, including IND, ANDA, and NDA documentation.
  • High-Potency & Specialty Manufacturing: Capabilities in oncology, hormones, sterile injectables, and complex formulations.
  • GMP Packaging & Serialization: Regulatory-compliant labeling and packaging with cold chain and export logistics.
  • Tech Transfer & Commercial Manufacturing: Seamless scale-up from lab to launch with validated, commercial-ready processes.

Advantages of Partnering with CDMOs in India

  • Global Regulatory Compliance: US FDA, EMA, MHRA, and WHO-GMP approved facilities with strong audit history.
  • Competitive Cost Structure: Significant cost savings without compromising on quality or speed.
  • Skilled Scientific Workforce: Access to highly qualified professionals in pharma R&D, manufacturing, and regulatory affairs.
  • Scalable Infrastructure: Large-volume production, flexible batch sizes, and dedicated high-containment suites.
  • Proven Global Track Record: Long-standing partnerships with top-20 global pharma and biotech companies.

CDMO Companies in India

Some of the leading CDMO companies in India include:

  • Shilpa Biologicals: A full-service CDMO in India offering end-to-end development and manufacturing for biologics and complex generics. [See CDMO profile]
  • Viswa Laboratories: Specializes in APIs, high-potency compounds, sterile products, and integrated drug development. [See CDMO profile]
  • SWISS Parenterals: Established in 1999, this Indian CDMO manufactures sterile products including ophthalmic drops, pre-filled syringes, eye ointments, ampoules, and inhalation solutions. [See CDMO profile]
  • 3xper: Your trusted CDMO/CRO partner providing tailored support from discovery to commercialization. [See CDMO profile]
  • Syfine Drugs: Based in Hyderabad, Syfine Drugs is an innovative pharmaceutical company engaged in high-quality manufacturing for global markets. [See CDMO profile]
  • Kemwell Biopharma Pvt Ltd: Biologics focused Contract Development and Manufacturing (CDMO) company providing services to global biopharmaceutical organisations. [See CDMO profile]
  • Hikal Ltd | Bangalore, India: cGMP process development, scale-up and manufacturing of small molecule APIs, NMEs and intermediates, from gram to kilogram and tonne scale, supporting projects from laboratory stage through commercial launch. [See CDMO profile]

Related Information

Leading CDMO Companies in APAC

Let MAI CDMO Network Help You Find the Right Indian CDMO Partner

Navigating the Indian CDMO ecosystem requires local expertise and trusted networks. MAI CDMO helps you identify the most suitable CDMO companies in India—with the right capabilities, certifications, and technical know-how to accelerate your program.

From early clinical batches to global commercial supply, our personalized matchmaking ensures you find a CDMO in India that fits your goals, timelines, and quality expectations.

Contact MAI CDMO Network today and connect with a trusted CDMO in India to bring your product from lab to launch.